WT1; Wilms tumor 1; GUD; WAGR; WIT-2; WT33; WT1 antibody; Wilms tumor 1 antibody; GUD antibody; WAGR antibody; WIT-2 antibody; WT33 antibody; Wilms tumor 1; Wilms tumor 1 / WT1

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Goat

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul (lot specific)

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Manufactured in an ISO 9001:2008 Certified Laboratory.

Small volumes of anti-WT1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Peptide ELISA (EIA), Western Blot (WB)

Peptide ELISA: Antibody detection limit dilution 1: 4000.
Western Blot: Approx 55kDa band observed in Human Kidney, Spleen and Testis lysates (calculated MW of 54.3kDa according to NP_000369.3). Recommended concentration: 1-3ug/ml.

(1ug/ml) staining of Human Spleen lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

33,086 Da

Wilms tumor 1

Wilms tumor protein

Wilms tumor protein

WT1_HUMAN

This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. In several variants, there is evidence for the use of a non-AUG (CUG) translation initiation codon upstream of, and in-frame with the first AUG. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated. [provided by RefSeq, Mar 2015]

WT1: a DNA binding protein and apparent transcriptional regulator. Recognizes and binds to the DNA sequence 5'-CGCCCCCGC-3'. Expressed in the kidney and a subset of hematopoietic cells. Defects in WT1 are the cause of Wilms tumor 1 (WT1), an embryonal malignancy of the kidney that affects approximately 1 in 10'000 infants and young children. It occurs both in sporadic and hereditary forms. Four alternatively spliced isoforms have been described.

Protein type: C2H2-type zinc finger protein; DNA-binding; Nucleolus; Transcription factor; Tumor suppressor

Chromosomal Location of Human Ortholog: 11p13

Cellular Component: cytoplasm; nuclear speck; nucleus

Molecular Function: double-stranded methylated DNA binding; protein binding; sequence-specific DNA binding; transcription factor activity; zinc ion binding

Biological Process: adrenal gland development; camera-type eye development; epithelial cell differentiation; germ cell development; glomerular basement membrane development; glomerulus development; gonad development; heart development; kidney development; male genitalia development; male gonad development; negative regulation of apoptosis; negative regulation of cell growth; negative regulation of cell proliferation; negative regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent; positive regulation of transcription, DNA-dependent; regulation of transcription from RNA polymerase II promoter; regulation of transcription, DNA-dependent; RNA splicing; sex determination; thorax and anterior abdomen determination; tissue development; ureteric bud branching; ureteric bud development; vasculogenesis

Disease: Aniridia; Denys-drash Syndrome; Frasier Syndrome; Meacham Syndrome; Mesothelioma, Malignant; Nephrotic Syndrome, Type 4; Wilms Tumor 1; Wilms Tumor, Aniridia, Genitourinary Anomalies, And Mental Retardation Syndrome

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.